LAG3 and metastatic melanoma: Lymphocyte-activation gene-3 (LAG-3, CD233) is referred to as a third IC, after the U.S. Food and Drug Administration approved the combination drug relatlimab/nivolumab (anti-LAG-3/anti-PD-1) for treatment of inoperable or metastatic melanoma in 2022 [16].